Metoprololtartrat Hexal

Metoprolol Tartrate, the active ingredient in Metoprololtartrat Hexal, is a beta blocker presented as a tablet for oral use. It lowers blood pressure, relieves angina and supports heart‑failure therapy in adult patients. GNH USA supplies Metoprololtartrat Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprololtartrat Hexal is a selective β1‑adrenergic blocker used in several cardiovascular conditions.

Hypertension: lowers systolic and diastolic pressure by reducing heart rate and cardiac output. Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. Post‑myocardial infarction: improves survival by limiting arrhythmias and remodeling. Chronic heart failure: enhances ventricular function and reduces hospitalization risk.

Metoprololtartrat Hexal may cause a range of adverse reactions.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities - Headache - Gastrointestinal discomfort (nausea, abdominal pain)

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm in patients with asthma or COPD - Acute heart failure exacerbation - Allergic reactions (rash, angioedema) - Depression or mood changes

Before initiating therapy, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control without excessive hypotension. Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. Use caution in asthma or COPD: β1‑selectivity may not fully prevent bronchospasm. Avoid abrupt discontinuation: taper to prevent rebound hypertension or tachycardia. Adjust dose in renal impairment: reduced clearance may require lower dosing. Store below 25°C: keep in the original pack, protect from moisture.

Metoprololtartrat Hexal can interact with several drug classes.

Major Interactions (Avoid): - Verapamil or diltiazem: additive negative‑inotropic and bradycardic effects. - Class IA antiarrhythmics (e.g., quinidine): increased risk of conduction abnormalities. - Clonidine abrupt withdrawal: may cause severe hypertension. - Insulin or oral hypoglycemics: can mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive response. - Diuretics (especially thiazides): risk of electrolyte disturbances. - NSAIDs: may reduce antihypertensive efficacy.